- Home
- TYRA vs GCMG Comparison
TYRA vs GCMG Comparison
Compare TYRA & GCMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- GCMG
- Stock Information
- Founded
- TYRA 2018
- GCMG 1971
- Country
- TYRA United States
- GCMG United States
- Employees
- TYRA N/A
- GCMG N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- GCMG Finance/Investors Services
- Sector
- TYRA Health Care
- GCMG Finance
- Exchange
- TYRA Nasdaq
- GCMG Nasdaq
- Market Cap
- TYRA 576.6M
- GCMG 631.4M
- IPO Year
- TYRA 2021
- GCMG N/A
- Fundamental
- Price
- TYRA $9.23
- GCMG $11.44
- Analyst Decision
- TYRA Strong Buy
- GCMG Hold
- Analyst Count
- TYRA 7
- GCMG 5
- Target Price
- TYRA $30.86
- GCMG $13.60
- AVG Volume (30 Days)
- TYRA 360.4K
- GCMG 467.2K
- Earning Date
- TYRA 08-06-2025
- GCMG 08-07-2025
- Dividend Yield
- TYRA N/A
- GCMG 3.83%
- EPS Growth
- TYRA N/A
- GCMG N/A
- EPS
- TYRA N/A
- GCMG 0.14
- Revenue
- TYRA N/A
- GCMG $530,455,000.00
- Revenue This Year
- TYRA N/A
- GCMG $2.72
- Revenue Next Year
- TYRA N/A
- GCMG $12.99
- P/E Ratio
- TYRA N/A
- GCMG $84.97
- Revenue Growth
- TYRA N/A
- GCMG 17.38
- 52 Week Low
- TYRA $6.42
- GCMG $9.56
- 52 Week High
- TYRA $29.60
- GCMG $14.48
- Technical
- Relative Strength Index (RSI)
- TYRA 41.84
- GCMG 24.78
- Support Level
- TYRA $10.11
- GCMG $12.38
- Resistance Level
- TYRA $10.68
- GCMG $11.94
- Average True Range (ATR)
- TYRA 0.79
- GCMG 0.28
- MACD
- TYRA -0.08
- GCMG -0.11
- Stochastic Oscillator
- TYRA 7.05
- GCMG 1.50
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About GCMG GCM Grosvenor Inc.
GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG and absolute return strategies. Company invest maximum in Private Equity. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.